Clintec expands UK headquarters and is presented with Queens Award for Enterprise – International Trade
Company's additional 4327-sq ft floor at Clintec’s Glasgow-based headquarters forms a fully dedicated centre of excellence for clinical research and quality assurance capabilities.
Clintec has been presented with the Queens Award for Enterprise 2017, in the category of International Trade - by Lord Provost, Eva Bolander in her capacity as Lord Lieutenant. The award ceremony coincides with the company's continued expansion – with the official opening of an additional 4327-sq ft floor at Clintec’s Glasgow-based headquarters, with the additional space forming a fully dedicated centre of excellence for clinical research and quality assurance capabilities.
The Queens Award, the highest business accolade that can be granted to any business operating within the UK, recognises outstanding corporate achievement and more than 20 years of consistent business success.
Dr Rabinder Buttar, Founder and CEO of Clintec, said: “We are honoured to have received the Queens Award for Enterprise for the second time – through which we celebrate 20 years of global success in clinical research. Furthermore, we are delighted to mark today with the expansion of our clinical operational capabilities and HQ office space for the next stage of company growth.”
She added: “Clintec’s high quality performance and service offering that we have consistently delivered to our customers over the past two decades, is well acknowledged. This includes our global footprint, with local expertise, flexibility, agility and high level of service with senior management closely involved in the innovative clinical development programmes we expertly deliver.”
The Lord Provost said: “Clintec International Ltd is a phenomenal success story. It therefore gave me immense pleasure, as Lord Lieutenant, to present its founder and Chief Executive, Dr Rabinder Buttar, with the Queen’s Award for International Trade. This dynamic Glasgow based company, which I was delighted to be given a tour of, has excelled itself in its short lifetime contributing to the city’s diverse business life. This represents its second Queen’s Award. It already has a highly deserved Queen’s Award for Enterprise.”
At the visit of the Lord Provost to Clintec’s HQ, Sophie Totten, Clintec’s first Master’s Graduate in International Clinical Research & Technology, was recognised for the Master’s Degree developed by Clintec jointly with Edinburgh Napier University. Sophie trained as a CRA at Clintec and has been part of the team that has excelled in delivering clinical monitoring services to a Clintec client - one of the top pharmaceutical companies in the world.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.